Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations. Shahnam A et al…
この記事を読む
記事一覧 2ページ
この記事を読む
末梢小型肺癌は細かく考える
Risk Factors for Locoregional Relapse After Segmentectomy:Supplementary Analysis of the JCOG0802/WJOG4607L Trial. Nakaga…
この記事を読む
オシメルチニブ心毒性のリスク因子
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population. Bak M et al.J Thorac Oncol.…
この記事を読む
PD後の免疫療法継続の利益はmGPSで分かる？
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. Saal J …
この記事を読む
「ドライバー変異なし」でもCGP検査で25%に標的遺伝子変異が見つかる
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database…
この記事を読む
大規模臨床試験データでのLIPIの有用性の検証
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc …
この記事を読む
抗PD-1抗体無効後のPD-L1抗体：アテゾリズマブ投与
Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Dire…
この記事を読む
分子標的治療後の有望な選択肢：ダトポタマブ デルクステカン
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results…
この記事を読む
POSEIDON試験の5年生存率、KEAP1/STK11＋に活路？
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overa…
この記事を読む
LAURA試験でのオシメルチニブの中枢神経系再発への抑制効果
Osimertinib after definitive chemoradiotherapy in unresectable stageⅢ epidermal growth factor receptor-mutated non-small…